In the BioHarmony Drug Report Database
Binimetinib
Mektovi (binimetinib) is a small molecule pharmaceutical. Binimetinib was first approved as Mektovi on 2018-06-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2. In addition, it is known to target serine/threonine-protein kinase B-raf. Mektovi’s patents are valid until 2033-10-18 (FDA).
Trade Name
|
Mektovi |
|---|---|
Common Name
|
binimetinib |
ChEMBL ID
|
CHEMBL3187723 |
Indication
|
melanoma |
Drug Class
|
Tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors |
Image (chem structure or protein)